Editeur

takeda-pharmaceutical-company-limited

Publications

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology s 63rd Annual Scientific Session

Documents

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Documents

Médias

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

17 pages

English

Lire

Infos

Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn s Disease

Documents

Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease

Documents

Médias

Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease

6 pages

English

Lire

Infos

Takeda s New Investigational Drug Vedolizumab Entered Phase 3 Clinical Trials in Japan For the Treatment of Ulcerative Colitis and Crohn s Disease

Documents

Takeda's New Investigational Drug Vedolizumab Entered Phase 3 Clinical Trials in Japan For the Treatment of Ulcerative Colitis and Crohn's Disease

Documents

Médias

Takeda's New Investigational Drug Vedolizumab Entered Phase 3 Clinical Trials in Japan For the Treatment of Ulcerative Colitis and Crohn's Disease

4 pages

English

Lire

Infos

Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)

Documents

Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)

Documents

Médias

Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)

2 pages

English

Lire

Infos

Takeda Anuncia la Aceptación a Trámite por parte de la EMA de Dos Terapias para Diabetes Tipo 2

Documents

Takeda Anuncia la Aceptación a Trámite por parte de la EMA de Dos Terapias para Diabetes Tipo 2

Documents

Médias

Takeda Anuncia la Aceptación a Trámite por parte de la EMA de Dos Terapias para Diabetes Tipo 2

2 pages

Español

Lire

Infos

Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes

Documents

Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes